MNG821
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.413
- E2F_TARGETS+0.341
- G2M_CHECKPOINT+0.313
- ANGIOGENESIS+0.296
- MTORC1_SIGNALING+0.277
- ANDROGEN_RESPONSE+0.241
- INTERFERON_GAMMA_RESPONSE+0.237
- CHOLESTEROL_HOMEOSTASIS+0.204
- HEDGEHOG_SIGNALING+0.188
- GLYCOLYSIS+0.178
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.393
- MYC_TARGETS_V2-0.368
- TGF_BETA_SIGNALING-0.328
- DNA_REPAIR-0.196
- WNT_BETA_CATENIN_SIGNALING-0.142
- IL6_JAK_STAT3_SIGNALING-0.134
- IL2_STAT5_SIGNALING-0.133
- MYC_TARGETS_V1-0.122
- NOTCH_SIGNALING-0.119
- UV_RESPONSE_UP-0.105
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 590d46bc-3db8-4e22-8550-b3e4ba0affba | — | — | 0.623 |
| 2 | TCGA-OR-A5JY-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.621 |
| 3 | 798dbd1d-9df6-42ab-8fe9-c48e416b3ec1 | — | — | 0.621 |
| 4 | bf5f606f-17ae-46bb-b687-7863ab3d97b1 | — | — | 0.601 |
| 5 | MNG1 | — | — | 0.591 |
| 6 | SRR5088820 | — | — | 0.582 |
| 7 | 88344 | EPN | Supratentorial EPN | 0.579 |
| 8 | R413 | — | — | 0.575 |
| 9 | SRR6079981 | — | — | 0.573 |
| 10 | 852508b0-5a5e-4730-8c70-6aabc0aa88be | — | — | 0.565 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.413 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.341 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.313 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.296 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.277 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.241 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.237 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.204 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.188 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.178 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.117 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.108 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.099 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.092 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.087 | Inavolisib | — uncovered |
| APOPTOSIS | 0.082 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.075 | Inavolisib | — uncovered |
| PEROXISOME | 0.072 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.072 | Remibrutinib | — uncovered |
| HYPOXIA | 0.066 | Idelalisib | — uncovered |